ClinicaliQ Trial Snapshot
- Chemotherapy Induced Cognitive Impairment — Recruiting • Oncology • NCT05740787.
- What is being tested: Investigation of chemotherapy-induced cognitive impairment ("chemo fog" or "chemobrain"), a poorly understood neurotoxic side-effect of chemotherapy that affects patient cognition and functional capacity but remains inadequately characterised in clinical research.
- Patient eligibility overview: The trial focuses on breast cancer patients who have reported subjective cognitive complaints following chemotherapy exposure, representing a population where this phenomenon has been predominantly documented and observed.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Chemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of "chemo fog" also known as "chemobrain" has not been fully investigated and is often based on comments of breast cancer patients attending outpatient clinics during and after their chemotherapy. Changes in thinking ability like lack of concentration, loss of memory and the inability to hold a thought or even a conversation has a significant impact on the lives of breast cancer patients. Without understanding what "chemobrain" is, and what causes it,…
Eligibility Snapshot
- : * Women and men >18 years * Diagnosed with HER2 negative breast cancer * Receiving EC-Taxane or Taxane only based chemotherapy * Able to communicate in English * Willing and able to give informed consent for participation in the study.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.